Intervention to reduce drug use and HIV incidence among high PrEP priority partnered YMSM

减少 PrEP 重点合作伙伴 YMSM 中吸毒和艾滋病毒发病率的干预措施

基本信息

  • 批准号:
    9926851
  • 负责人:
  • 金额:
    $ 92.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-07-01 至 2022-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary CDC recommendations identify MSM in non-monogamous relationships and those in relationships with an HIV positive partner as candidates for PrEP. Estimates suggest as many as 79% of new HIV infections among young MSM (YMSM; ages 18-29) are transmitted between main partners. Drug use is an established correlate of HIV transmission risk. For partnered men, relational factors (e.g., sexual agreements) contextualize drug use and both drug use and sexual agreements predict receptivity to PrEP. Together, these findings point to the need for integrated intervention services – targeting drug use and sexual health –tailored for partnered YMSM. Such services are essential to addressing the HIV epidemic in the US. In response, our team has developed a 4-session MI-based intervention targeting PrEP uptake/adherence, HIV TRB, and drug use among partnered YMSM. PARTNER (Prevention And Risk: Treatment with a New Emphasis on Relationships) is delivered to individual YMSM in relationships (not couples), which enhances the scalability of the proposed intervention. Our preliminary pilot work has established the acceptability and feasibility of PARTNER. The primary goal of the current study is to test the efficacy of PARTNER relative to an attention-matched educational control condition used in previously funded NIH studies with HIV-negative YMSM. We propose to recruit 240 HIV-negative partnered YMSM who report recent drug use and sexual behavior consistent with CDC guidance for PrEP candidacy into a randomized control trial. As part of a secondary aim, this project seeks to enhance the range of biological measures for PrEP adherence currently available. The field standard for assessing tenofovir metabolites is dried blood spot assay; however, fingernail assay has high acceptability and lower cost. We propose to validate fingernail samples for PrEP adherence by correlating results obtained from fingernail samples with dried blood spot data. The study team is led by Dr. Tyrel J. Starks (PI), a new investigator with substantial experience in the study of relationship factors associated with sexual health and MSM in relationships. He has collaborated on numerous projects examining the nature of sexual agreements and their association with substance use and HIV transmission risk behavior. He is supported by a study team which includes Dr. Jeffrey Parsons, the PI of multiple intervention studies targeting sexual health and substance use. He is also joined by Dr. Monica Gandhi, an expert in biological assessment for PrEP adherence who has pioneered the use of novel matrices in previous NIH- funded studies. The team brings extensive experience in behavioral intervention research, relationship research, and biomedical assessment.
项目摘要 CDC建议识别非一夫一妻制关系中的MSM和 与艾滋病毒阳性伴侣的关系作为PrEP的候选人。 年轻男男性行为者(YMSM; 18-29岁)中79%的新艾滋病毒感染是在 主要合作伙伴。吸毒是艾滋病毒传播风险的一个既定相关因素。对于有伴侣的男人来说, 相关因素(例如,性协议)的背景下使用毒品和吸毒, 性协议预测对PrEP的接受性。总之,这些发现表明需要 综合干预服务-针对吸毒和性健康-为合作伙伴量身定制 YMSM。这些服务对于解决美国的艾滋病毒流行至关重要。 作为回应,我们的团队开发了一种针对PrEP的4节基于MI的干预措施 合作的YMSM中的吸收/依从性、艾滋病毒TRB和药物使用。合作伙伴(预防 和风险:治疗与关系的新重点)是交付给个人YMSM在 关系(而不是夫妇),这增强了拟议干预的可扩展性。我们 初步试点工作已确定PARTNER可被接受和可行。主 本研究的目的是测试PARTNER相对于注意力匹配的 教育控制条件用于先前资助的NIH研究与艾滋病毒阴性YMSM。 我们建议招募240名HIV阴性的YMSM伴侣,他们报告最近使用毒品, 性行为符合CDC对PrEP候选人资格的指导,纳入随机对照 审判作为第二个目标的一部分,该项目旨在提高生物多样性的范围。 目前已有PrEP依从性措施。替诺福韦的现场评价标准 代谢物是干血斑试验;然而,指甲试验具有高可接受性, 更低的成本我们建议通过关联结果来验证指甲样本的PrEP依从性 从指甲样品中获得的干血斑数据。 该研究小组由Tyrel J. Starks博士(PI)领导,他是一位具有丰富经验的新研究者 在研究与性健康和男男性接触者的关系因素。他 在许多项目上进行了合作,研究性协议的性质及其 与物质使用和艾滋病毒传播风险行为的关系。他的研究支持了 团队,其中包括杰弗里帕森斯博士,PI的多个干预研究,针对性 健康和物质使用。生物学专家莫妮卡·甘地博士也与他一起 评估PrEP依从性,他在以前的NIH中率先使用了新型基质- 资助的研究。该团队在行为干预研究方面拥有丰富的经验, 关系研究和生物医学评估。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tyrel J Starks其他文献

Tyrel J Starks的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tyrel J Starks', 18)}}的其他基金

Couples Motivational Interviewing to reduce drug use and HIV risk in vulnerable male couples
夫妻动机访谈,以减少弱势男性夫妇的吸毒和艾滋病毒风险
  • 批准号:
    10757544
  • 财政年份:
    2023
  • 资助金额:
    $ 92.2万
  • 项目类别:
Expanding the potential of couples HIV testing: Adjunct modules to reduce drug use among vulnerable male couples
扩大夫妇艾滋病毒检测的潜力:减少弱势男性夫妇吸毒的辅助模块
  • 批准号:
    10403968
  • 财政年份:
    2020
  • 资助金额:
    $ 92.2万
  • 项目类别:
Evaluating the efficacy of annual CHTC retesting among male couples at high risk of HIV infection
评估 HIV 感染高危男性夫妇每年进行 CHTC 重新检测的效果
  • 批准号:
    10700394
  • 财政年份:
    2020
  • 资助金额:
    $ 92.2万
  • 项目类别:
Expanding the potential of couples HIV testing: Adjunct modules to reduce drug use among vulnerable male couples
扩大夫妇艾滋病毒检测的潜力:减少弱势男性夫妇吸毒的辅助模块
  • 批准号:
    10079536
  • 财政年份:
    2020
  • 资助金额:
    $ 92.2万
  • 项目类别:
Expanding the potential of couples HIV testing: Adjunct modules to reduce drug use among vulnerable male couples
扩大夫妇艾滋病毒检测的潜力:减少弱势男性夫妇吸毒的辅助模块
  • 批准号:
    10217086
  • 财政年份:
    2020
  • 资助金额:
    $ 92.2万
  • 项目类别:
Expanding the potential of couples HIV testing: Adjunct modules to reduce drug use among vulnerable male couples
扩大夫妇艾滋病毒检测的潜力:减少弱势男性夫妇吸毒的辅助模块
  • 批准号:
    10626930
  • 财政年份:
    2020
  • 资助金额:
    $ 92.2万
  • 项目类别:
Intervention to reduce drug use and HIV incidence among high PrEP priority partnered YMSM
减少 PrEP 重点合作伙伴 YMSM 中吸毒和艾滋病毒发病率的干预措施
  • 批准号:
    9920804
  • 财政年份:
    2017
  • 资助金额:
    $ 92.2万
  • 项目类别:
Intervention to reduce drug use and HIV incidence among high PrEP priority partnered YMSM
减少 PrEP 重点合作伙伴 YMSM 中吸毒和艾滋病毒发病率的干预措施
  • 批准号:
    10152563
  • 财政年份:
    2017
  • 资助金额:
    $ 92.2万
  • 项目类别:
Examining community-based effectiveness of a substance use and HIV risk reduction intervention for young men of color
检查基于社区的针对有色人种年轻男性的药物滥用和艾滋病毒风险降低干预措施的有效性
  • 批准号:
    9920523
  • 财政年份:
    2016
  • 资助金额:
    $ 92.2万
  • 项目类别:
Addressing substance use through CVCT
通过 CVCT 解决物质使用问题
  • 批准号:
    8810662
  • 财政年份:
    2014
  • 资助金额:
    $ 92.2万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 92.2万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 92.2万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 92.2万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 92.2万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 92.2万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 92.2万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 92.2万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 92.2万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 92.2万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 92.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了